http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-112013011883-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aac4a747e60a2949ac458ccdbb76fdea |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-416 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-434 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-608 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-61 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-436 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-022 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-16 |
| filingDate | 2011-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e08d2464ec8e79e4e810339fff44dccb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b768823ea0db540c2a3b9f7d4c2a6d6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab68b92daeeeafd806170c172c0e0bfb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_303d57a535cb48db61620f6b2283ae50 |
| publicationDate | 2020-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-112013011883-A2 |
| titleOfInvention | local vascular distribution of a combination of a2a adenosine receptor agonists / phosphodiesterase inhibitor to reduce myocardial damage |
| abstract | local vascular distribution of a combination of a2a adenosine receptor agonists / phosphodiesterase inhibitor to reduce myocardial damage. the present invention relates to a stent or other implantable medical device for the local delivery of a selective adenosine receptor agonist, which can be used in combination with other therapeutic agents to reduce a myocardial injury that results from a acute myocardial infarction. as soon as possible following an acute myocardial infarction, a stent or other suitable device that understands and is capable of delivering a selective adenosine receptor agonist is positioned in the blood vessel in the occlusion responsible for causing the infarction. once in position, the stent or other intraluminal device is deposited to remove the occlusion and restore blood flow to the specific area, region or volume of tissue in the heart. for a given period of time, the selective adenosine receptor agonist, alone or in combination with other therapeutic agents, elutes from the stent or other device within the downstream flow of coronary blood within the hypoxic cardiac tissue for a sufficient time to reduce the level of myocardial injury. |
| priorityDate | 2010-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 338.